These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36849728)

  • 21. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study.
    Sujenthiran A; Nossiter J; Parry M; Charman SC; Cathcart PJ; van der Meulen J; Clarke NW; Payne H; Aggarwal A
    Radiother Oncol; 2018 Aug; 128(2):357-363. PubMed ID: 29773442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.
    Samuelian JM; Callister MD; Ashman JB; Young-Fadok TM; Borad MJ; Gunderson LL
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1981-7. PubMed ID: 21477938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity.
    Franzese C; Badalamenti M; Baldaccini D; D'Agostino G; Comito T; Franceschini D; Clerici E; Navarria P; Reggiori G; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2021 Feb; 197(2):133-140. PubMed ID: 33006025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A randomized study of intensity-modulated radiation therapy versus three dimensional conformal radiation therapy for pelvic radiation in patients of post-operative treatment with gynecologic malignant tumor].
    Ni J; Yin ZM; Yuan SH; Liu NF; Li L; Xu XX; Lou HM
    Zhonghua Fu Chan Ke Za Zhi; 2017 Mar; 52(3):168-174. PubMed ID: 28355688
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy.
    Onal C; Yuce Sari S; Yavas G; Oymak E; Birgi SD; Yigit E; Guler OC; Gultekin M; Akyurek S; Yildiz F
    Acta Oncol; 2021 Sep; 60(9):1154-1160. PubMed ID: 33999750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Lukez A; Handorf E; Mendenhall NP; Henderson RH; Stish BJ; Davis BJ; Hallman M; Horwitz EM; Vapiwala N; Wong JK
    Prostate; 2024 Mar; 84(4):395-402. PubMed ID: 38108113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
    White EC; Murphy JD; Chang DT; Koong AC
    Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy.
    Shimoyachi N; Yoshioka Y; Sasamura K; Yonese J; Yamamoto S; Yuasa T; Soyano T; Kozuka T; Oguchi M
    Adv Radiat Oncol; 2021; 6(6):100753. PubMed ID: 34934854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
    Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
    Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
    Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA
    Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique.
    Hardee ME; Raza S; Becker SJ; Jozsef G; Lymberis SC; Hochman T; Goldberg JD; DeWyngaert KJ; Formenti SC
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e415-23. PubMed ID: 22019349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer.
    Wang MH; Vos LJ; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Ghosh S; Field C; Fallone BG; Murtha AD
    Pract Radiat Oncol; 2021; 11(5):384-393. PubMed ID: 33705985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
    Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.